Enhanced and persistent levels of interleukin (IL)‐17+CD4+ T cells and serum IL‐17 in patients with early inflammatory arthritis

Prognosis of patients with early inflammatory arthritis (EIA) is highly variable. The aim of this study was to compare, longitudinally and cross‐sectionally, the levels of cytokine‐expressing cells in peripheral blood (PB) from patients with EIA to those in established rheumatoid arthritis (RA) and healthy controls (HC). PB mononuclear cells from HC (n = 30), patients with EIA (n = 20) or RA (n = 38) were stimulated with phorbol myristate acetate (PMA)/ionomycin for 3 h, and stained for cell markers and cytokines. Serum cytokines and chemokines were measured by Luminex. Patients with EIA were reassessed at 6 and 12 months. The percentage of interleukin (IL)‐17+interferon (IFN)‐γ−CD4+ T cells [T helper type 17 (Th17)] was increased in RA and EIA versus HC. Serum IL‐1β, IL‐2, IL‐4 IL‐17 and macrophage inflammatory protein (MIP)‐1α were increased in RA and EIA versus HC. IL‐1Ra, IL‐15 and IFN‐α were increased in EIA versus HC. IL‐6 and tumour necrosis factor (TNF)‐α was increased in RA but not EIA versus HC. Disease activity scores in EIA patients improved over 12 months' treatment. Th17 percentage at baseline was correlated with both rheumatoid factor (RF) titre and functional deficit at 12 months. Baseline levels of serum granulocyte–macrophage colony‐stimulating factor (GM‐CSF), IL‐6 and IL‐8 were correlated with Larsen score at 12 months. There were no significant changes in cytokine‐expressing CD4+T cells over time, although the percentage of IL‐6+ monocytes increased. IL‐17+CD4+ T cells and serum IL‐17 levels are increased in EIA. IL‐6‐expressing monocytes increase during the first year of disease, irrespective of disease‐modifying anti‐rheumatic drug (DMARD) therapy. We observed incomplete clinical responses, suggesting EIA patients need more intensive early therapy.

[1]  E. Martı́n-Mola,et al.  Frequency of Th17 CD4+ T Cells in Early Rheumatoid Arthritis: A Marker of Anti-CCP Seropositivity , 2012, PloS one.

[2]  X. Mariette,et al.  Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort , 2012, Annals of the rheumatic diseases.

[3]  B. Cai,et al.  Disturbed Th17/Treg balance in patients with rheumatoid arthritis , 2012, Rheumatology International.

[4]  I. González-Álvaro,et al.  Interleukin 15 Levels in Serum May Predict a Severe Disease Course in Patients with Early Arthritis , 2011, PloS one.

[5]  Chi-Chen Lin,et al.  Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy , 2011, Arthritis research & therapy.

[6]  J. Hazes,et al.  The epidemiology of early inflammatory arthritis , 2011, Nature Reviews Rheumatology.

[7]  M. Kamal,et al.  Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA , 2011, Clinical Rheumatology.

[8]  E. Lubberts,et al.  Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. , 2011, Arthritis and rheumatism.

[9]  J. Weyler,et al.  Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression. , 2010, Rheumatology.

[10]  H. Canhão,et al.  Identification of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis , 2010, Journal of Translational Medicine.

[11]  P. Tak,et al.  Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis , 2010, Science Translational Medicine.

[12]  A. Skapenko,et al.  Role of Th17 cells in human autoimmune arthritis. , 2010, Arthritis and rheumatism.

[13]  I. González-Álvaro,et al.  Characterization of serum interleukin-15 in healthy volunteers and patients with early arthritis to assess its potential use as a biomarker. , 2010, European cytokine network.

[14]  Leonie S. Taams,et al.  Linking Power Doppler Ultrasound to the Presence of Th17 Cells in the Rheumatoid Arthritis Joint , 2010, PloS one.

[15]  A. Silman,et al.  Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .

[16]  M. Genovese,et al.  LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. , 2010, Arthritis and rheumatism.

[17]  Simon A. Jones,et al.  Interferon-γ inhibits interleukin-1β-induced matrix metalloproteinase production by synovial fibroblasts and protects articular cartilage in early arthritis , 2010, Arthritis research & therapy.

[18]  J. Rocklöv,et al.  Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. , 2010, Arthritis and rheumatism.

[19]  Wei He,et al.  The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients , 2010, Rheumatology International.

[20]  V. Kuchroo,et al.  Interleukin-17 and type 17 helper T cells. , 2009, The New England journal of medicine.

[21]  J. Highton,et al.  Monocyte Derived Interleukin (IL)-23 Is an Important Determinant of Synovial IL-17A Expression in Rheumatoid Arthritis , 2009, The Journal of Rheumatology.

[22]  Y. Kageyama,et al.  Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis , 2009, Modern rheumatology.

[23]  J. Goodall,et al.  Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. , 2009, Arthritis and rheumatism.

[24]  D. Speiser,et al.  Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. , 2008, Arthritis and rheumatism.

[25]  Mikkel Ostergaard,et al.  Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome. , 2008, The Journal of rheumatology.

[26]  Y. Iwamoto,et al.  Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[27]  V. Farewell,et al.  Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[28]  Simon A. Jones,et al.  Interferon-gamma protects against the development of structural damage in experimental arthritis by regulating polymorphonuclear neutrophil influx into diseased joints. , 2007, Arthritis and rheumatism.

[29]  J. Edmonds,et al.  Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). , 2006, Arthritis and rheumatism.

[30]  C. Gordon,et al.  Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin , 2005, Arthritis research & therapy.

[31]  T. Spector,et al.  The role of pregnancy in the course and aetiology of rheumatoid arthritis , 1992, Clinical Rheumatology.

[32]  L. Joosten,et al.  Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. , 2004, Arthritis and rheumatism.

[33]  P. Miossec.  Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. , 2003, Arthritis and rheumatism.

[34]  B. Kirkham,et al.  Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. , 2002, Arthritis and rheumatism.

[35]  S. Hwang,et al.  Inhibition of interleukin‐12 production by auranofin, an anti‐rheumatic gold compound, deviates CD4+ T cells from the Th1 to the Th2 pathway , 2001, British journal of pharmacology.

[36]  L. Joosten,et al.  IL-1-Independent Role of IL-17 in Synovial Inflammation and Joint Destruction During Collagen-Induced Arthritis1 , 2001, The Journal of Immunology.

[37]  A. Saudan,et al.  Introduction to reading radiographs by the Scott modification of the Larsen method. , 1999, The Journal of rheumatology.

[38]  B. Mazières,et al.  Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. , 1998, Arthritis and rheumatism.

[39]  A. Duits,et al.  Proinflammatory cytokine production and cartilage damage due to rheumatoid synovial T helper-1 activation is inhibited by interleukin-4. , 1995, Annals of the rheumatic diseases.

[40]  T. Mosmann,et al.  Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? , 1993, Immunology today.

[41]  J. Banchereau,et al.  Low levels of interleukin-4 and high levels of transforming growth factor beta in rheumatoid synovitis. , 2010, Arthritis and rheumatism.

[42]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[43]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.